Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pembrolizumab Plus Bevacizumab and Chemotherapy as First-Line Treatment for Advanced or Metastatic Non-Squamous NSCLC Patients With EGFR Exon 20 Insertion Mutation: An Open-Label, Single-Arm, Phase II Trial

Next Previous
Trial Profile

Pembrolizumab Plus Bevacizumab and Chemotherapy as First-Line Treatment for Advanced or Metastatic Non-Squamous NSCLC Patients With EGFR Exon 20 Insertion Mutation: An Open-Label, Single-Arm, Phase II Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Dexamethasone (Primary) ; Folic acid (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Vitamin B complex (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 05 Jun 2023 Planned initiation date (estimated date of first participant enrollment) changed from 30 Mar 2023 to 30 Jun 2023.
  • 05 Jun 2023 Status changed from not yet recruiting to recruiting.
  • 07 Mar 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top